Innovotech AGM Presentation April 19 2011

Annual General Meeting
19 April 2011
Edmonton, Alberta
Innovotech Inc.

Innovotech Inc
A G E N D A
Welcome
Formal Administrative Business
Adjournment of AGM
Business Update
Q&A

Innovotech Inc.Pursuing the Greatest Opportunityin Microbiology Since Penicillin
Annual General Meeting
19 April 2011

Forward Looking Statements
This presentation contains forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Forward-looking statements may include words such as “expects”, “plans”, “will”, “believes”, “estimates”, “intends”, “may”, and other words of similar meaning and may relate to future financial performance, business strategies, or safety and efficacy of unapproved products.
Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; the demand for new products and the impact of competitive products, service and pricing; availability and cost of raw materials; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defence; the Company’s exposure to lawsuits and other matters beyond the control of management.

Detachment and reversion to planktonic growth
Opportunity
Planktonic (free-floating)
Much knowledge
All regulatory standards, disinfectants, diagnostics and antibiotics
20% of the problem
Biofilm (community of organisms)
Little knowledge
Few products
80% of the problem
FACT: 17 million patients (US) suffer from biofilm infections
Of those patients, 550,000 die
Cost to healthcare = $94 billion

Opportunity
New hospital superbugs proving resistant to antibiotics
A new hospital superbug resistant to antibiotics has been brought into the country by patients returning home after surgery abroad.
13 Aug 2009
Health Authorities Link 12 Deaths to Contaminated Meat
Twelve deaths in Canada have now been linked to listeriosis, according to federal health officials who said Monday the deaths are among 26 confirmed cases of an outbreak across the country stemming from contaminated meat.Monday, Aug. 25, 2008
Florida Orange Acres Fall as Farmers Cut Sick Trees
Orange-crop acreage in Florida, the world's second-biggest producer, fell to a 24-year low as growers removed trees to slow the spread of disease affecting citrus crops, the U.S Department of Agriculture said.
Thursday, September 23, 2010

Market Opportunity
One Platform
Technology …
… Many Product Opportunities

Product Pipeline
One Platform Technology – Many Product Opportunities
$2B
$6B total*
$13B
$5B
*
Phase
of Development
Market Potential
Market
Introduction
Vet
Regulatory
Research
&
Development
bioFILM PA™
Agress®
Sani-Lux™
Gram +/-ve test
AgreGuard™
Product
AgreGuard™ is a Silver technology for coating catheters; Sani Lux™ is a hard surface disinfectant

Path to Market - Healthcare
Market Leaders
Becton Dickinson
BioMérieux
Siemens
Trek
Product - bioFILM PA™ (Susceptibility test)
Veterinary – world
Israel
Human testing service
Alberta Health Service
Sales
Worldwide partner?
Proof of Sales
LevPharm – Israel
Veterinary partner
Regulatory
Health Canada Approval
Israel Reimbursement
Partner
Sick Kids trial
U of Alberta CF clinic
- Clinical & health economic evaluation
Proof of Concept
bioFILM PA™

Path to Market - Agriculture
Market Leaders
Syngenta
Monsanto
Bayer
Dow
DuPont
BASF
Product – Agress® (Crop Protection)
EPA – pre-submission consult (Feb 2011)
TSG - managed more silver product registrations with EPA than any other consultant
Proof of Sales
Syngenta:
Worldwide, US, Canada
Include in all products
Extends patent protection
Regulatory
Partner
Seed Treatment Field Trials:
Efficacy, costing
Pulse, horticulture, potato
Proof of Concept
Agress®
* Potential discontinuation of imported streptomycin-treated seed to enter Canada from the U.S. as early as 2012

Agress® - Bean Blight Seed Treatment
Untreated
Naturally infested bean seed
Untreated
Agress®
Untreated
Agress®

Financial Highlights
Revenue for 2010 – $1.6M*
R&D expenditures - $764,000*
Net burn rate - $80,000/month*
Cash - $767,000*
$4.5M raised since inception = 3 late stage products
Shares outstanding – 24M*
Approx. 25% held by insiders
Options = 850,400, Warrants = 0*
Patents – 8 excl. license (UofCalgary), 15 IOT
* As of December 31, 2010

Milestones
Revenue (000,000)

Summary
New hospital superbugs proving resistant to antibiotics
A new hospital superbug resistant to antibiotics has been brought into the country by patients returning home after surgery abroad.
13 Aug 2009
Health Authorities Link 12 Deaths to Contaminated Meat
Twelve deaths in Canada have now been linked to listeriosis, according to federal health officials who said Monday the deaths are among 26 confirmed cases of an outbreak across the country stemming from contaminated meat.Monday, Aug. 25, 2008
Florida Orange Acres Fall as Farmers Cut Sick Trees
Orange-crop acreage in Florida, the world's second-biggest producer, fell to a 24-year low as growers removed trees to slow the spread of disease affecting citrus crops, the U.S Department of Agriculture said.
Thursday, September 23, 2010

Contact Information
Ken Boutilier, President
Innovotech Inc.
ken.boutilier@innovotech.ca
Ph: 780-448-0585 ext 221
Fax: 780-424-0941

People - Board
Lorne Babiuk, PhD
Kerry Brown , CA
Bruce Hirsche, LLM
Corporate Secretary
Wolfgang Muhs, PhD
Chairman of the Board
John Pinsent , CA
Gerard Tertzakian, PhD
James Timourian, PhD
Chief Financial Officer
Vice President Research, University of Alberta. Former-Director, VIDO, University of Saskatchewan, a renowned vaccine development institute.
Former-Chairman, Foundation Equity Corporation, a successful technology venture capital firm.
Partner with Parlee McLaws LLP, specializing in intellectual property and technology development.
Executive in pharmaceutical manufacturing at Laporte PLC, Degussa GmbH and Rhodia Pharma Solutions. CEO of Raylo Chemicals.
Founding Partner, St Arnaud Pinsent, Steman a technology-focused chartered accounting firm. Former Director of Technology at Ernst and Young LLP.
Experience in the creation, management, and financing of knowledge-based companies. Former-Chair & CEO of Innovotech, Raylo Chemicals and Cytovax Biotechnologies.
Former CFO at Raylo Chemicals. Former Chairman of the Board at Ricon Resins Inc. Serial investor and board member in over 15 early-stage technology companies.

People – Senior Management
Former senior manager at Glaxo SmithKline Inc, McKesson Canada and Canada Safeway Pharmacies Ltd with experience in operations and marketing spanning biotechnology, pharmaceutical manufacturing and distribution, and retail pharmacy.
World recognized biofilm expert. Experienced researcher and entrepreneur holding over 35 patents in medical and veterinary science and over 170 published papers. Inventor of the MBEC Assay™ and founder of MBEC Biofilm Technologies.
Former CFO at Raylo Chemicals. Former Chairman of the Board at Ricon Resins Inc. Serial investor and board member in over 15 early-stage technology companies.
Ken Boutilier, MBA
President and CEO
Merle Olson, DVM
Research Director
Jim Timourian, PhD
Chief Financial Officer

http://www.innovotech.ca	368
http://innovotech.ca	121
url_unknown	3
http://webcache.googleusercontent.com	2
http://www.slideshare.net	1

Innovotech AGM Presentation April 19 2011

by Innovotech Inc. on May 16, 2011

Accessibility

Categories

Upload Details

Usage Rights

5 Embeds 495

Statistics

Innovotech AGM Presentation April 19 2011 — Presentation Transcript